These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
148 related items for PubMed ID: 9179505
1. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Welch SP. Drug Alcohol Depend; 1997 Apr 14; 45(1-2):39-45. PubMed ID: 9179505 [Abstract] [Full Text] [Related]
2. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. Welch SP, Dunlow LD, Patrick GS, Razdan RK. J Pharmacol Exp Ther; 1995 Jun 14; 273(3):1235-44. PubMed ID: 7791096 [Abstract] [Full Text] [Related]
5. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. Welch SP, Huffman JW, Lowe J. J Pharmacol Exp Ther; 1998 Sep 14; 286(3):1301-8. PubMed ID: 9732392 [Abstract] [Full Text] [Related]
6. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. Mason DJ, Lowe J, Welch SP. Eur J Pharmacol; 1999 Aug 13; 378(3):237-48. PubMed ID: 10493099 [Abstract] [Full Text] [Related]
7. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Pertwee RG, Stevenson LA, Griffin G. Br J Pharmacol; 1993 Dec 13; 110(4):1483-90. PubMed ID: 8306090 [Abstract] [Full Text] [Related]
8. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Smith FL, Fujimori K, Lowe J, Welch SP. Pharmacol Biochem Behav; 1998 May 13; 60(1):183-91. PubMed ID: 9610941 [Abstract] [Full Text] [Related]
9. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. J Pharmacol Exp Ther; 1994 Jul 13; 270(1):219-27. PubMed ID: 8035318 [Abstract] [Full Text] [Related]
10. Discriminative stimulus effects of anandamide in rats. Wiley J, Balster R, Martin B. Eur J Pharmacol; 1995 Mar 24; 276(1-2):49-54. PubMed ID: 7781695 [Abstract] [Full Text] [Related]
11. (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure. Burkey RT, Nation JR. Exp Clin Psychopharmacol; 1997 Aug 24; 5(3):195-202. PubMed ID: 9260067 [Abstract] [Full Text] [Related]
12. Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Mallet PE, Beninger RJ. Life Sci; 1998 Aug 24; 62(26):2431-9. PubMed ID: 9651110 [Abstract] [Full Text] [Related]
15. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. Wiley JL, Golden KM, Ryan WJ, Balster RL, Razdan RK, Martin BR. Pharmacol Biochem Behav; 1997 Dec 24; 58(4):1139-43. PubMed ID: 9408225 [Abstract] [Full Text] [Related]
18. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. O'Sullivan SE, Kendall DA, Randall MD. Eur J Pharmacol; 2005 Jan 10; 507(1-3):211-21. PubMed ID: 15659311 [Abstract] [Full Text] [Related]